Cardio-Oncology Fellowship

What Is a Cardio-Oncology Fellowship?

Cardio-oncology is the clinical and investigative discipline focused on cardiovascular complications that arise from cancer itself and from cancer-directed therapies — chemotherapy, targeted agents, immunotherapy, and radiation — as well as on long-term cardiovascular risk in survivorship. The field sits at a genuine intersection: patients are managed jointly by cardiologists who understand oncologic treatment plans and oncologists who understand cardiac risk stratification. Neither background alone is sufficient for the most complex cases.

Demand for this expertise has grown in step with cancer survival rates. As more patients survive malignancy, the downstream burden of treatment-related cardiotoxicity, accelerated coronary disease, heart failure, arrhythmia, and cardiac amyloidosis has become clinically significant at scale. Cardio-oncology fellowship training is the structured pathway to building subspecialty-level competence in this patient population.

Accreditation Status — What You Need to Know

As of this registry's publication, cardio-oncology fellowships are not accredited by the Accreditation Council for Graduate Medical Education (ACGME). This is not an oversight or a temporary gap; it reflects where the field currently sits in the ACGME specialty recognition pipeline. Programs operating today are either institutionally sponsored — meaning the hospital or medical school funds and governs the fellowship independently — or structured under the auspices of professional societies such as the International Cardio-Oncology Society (ICOS) or the American College of Cardiology (ACC).

What non-accreditation means in practice:

• Trainee protections vary. ACGME oversight establishes duty hour limits, grievance procedures, program evaluation requirements, and minimum case volume standards. Without it, these protections depend entirely on institutional policy. Evaluate each program's governance documentation before accepting an offer.
• No standardized curriculum. Programs define their own rotation structure, scholarly requirements, and evaluation methods. Quality varies. The framework in this page helps you ask the right questions.
• No board exam pathway through ACGME at this time. There is no standalone American Board of Internal Medicine (ABIM) certifying examination for cardio-oncology. See the board certification section below for the current landscape.
• ACGME accreditation may come. The field has been actively discussing formal accreditation. If accreditation status is important to your decision, verify directly with the ACGME specialty committee and individual programs for the most current development; this changes faster than editorial review cycles.

The absence of accreditation does not reflect poorly on the clinical substance of the training. It reflects the normal lifecycle of an emerging subspecialty. Plan around what accreditation actually governs — not a judgment about the field's legitimacy.

Training Duration and Structure

Most cardio-oncology fellowships are structured as one-year programs. A subset of programs, particularly those at major academic or NCI-designated cancer centers, offer a second research year for fellows who want to develop an independent investigative portfolio before entering the faculty market.

A typical one-year program distributes training across several core rotations:

• Inpatient cardio-oncology consult service: the clinical anchor of training; fellows manage cardiovascular emergencies and complications in actively treated oncology inpatients, including arrhythmias, myocarditis, pericardial disease, and acute coronary syndromes in patients with active malignancy
• Cardiac imaging: echocardiography, cardiac MRI, and nuclear cardiology for cardiotoxicity surveillance; fellows typically develop advanced echocardiographic skills including strain imaging
• Heart failure: management of chemotherapy-related cardiomyopathy, often in collaboration with advanced heart failure teams
• Embedded oncology exposure: time on medical oncology, hematology, or radiation oncology services to develop fluency in treatment protocols, staging language, and prognosis framing
• Outpatient cardio-oncology clinic: pre-treatment cardiac risk stratification, survivorship surveillance, and longitudinal management of cardiovascular complications

Research time, even in one-year programs, is typically protected. Most programs expect fellows to complete at least one manuscript or abstract submission. Two-year programs formalize this into a structured research year with mentored grant development.

Prerequisites and Eligibility

The standard prerequisite for cardio-oncology fellowship is completion of an ACGME-accredited three-year cardiovascular disease fellowship. This is the most common entry pathway and the one assumed by most programs in their recruitment materials.

A smaller but meaningful number of programs also accept fellows who have completed an ACGME-accredited hematology/oncology fellowship. Programs with this dual entry point are typically structured to provide heavier cardiology procedural and imaging exposure for the oncology-trained fellow. If you are entering from hematology/oncology, ask directly how imaging competencies are structured for your track — a program that expects both entry types to reach the same echocardiographic standard needs to account for the differential starting point.

Some programs specify additional subspecialty training in cardiac imaging, heart failure, or advanced echocardiography as preferred (not required) prior experience. Board certification in cardiovascular disease is typically expected, not merely eligibility.

Clinical Scope and Competencies

Well-structured programs build competence across five core clinical domains:

• Cardiotoxicity surveillance and management: understanding dose-dependent and idiosyncratic mechanisms of cardiac injury from anthracyclines, HER2-targeted agents, tyrosine kinase inhibitors, and other chemotherapeutic classes; establishing and interpreting surveillance imaging protocols; making recommendations about continuation, dose modification, or discontinuation in the context of oncologic urgency
• Immunotherapy-related cardiovascular events: recognition and management of immune checkpoint inhibitor-associated myocarditis, which carries significant mortality risk; this is one of the fastest-evolving clinical areas in the field and programs should have recent, hands-on experience with these cases, not just didactic coverage
• Radiation-associated heart disease: late cardiovascular effects of thoracic radiation including accelerated coronary artery disease, valvular disease, pericardial disease, and conduction abnormalities; long-term survivorship management for patients treated decades earlier
• Cardiac amyloidosis in the oncology context: differentiation of AL amyloid (plasma cell dyscrasia-associated) from ATTR amyloid; management at the intersection of hematologic malignancy treatment and structural heart disease
• Perioperative cardiac risk stratification: evaluation and optimization of cardiac risk in oncology patients undergoing major surgery; familiarity with frailty assessment, functional capacity tools, and shared decision-making when curative resection and cardiac risk intersect

Research and Academic Opportunities

Cardio-oncology is a relatively young field with an underdeveloped evidence base. Most of what drives clinical practice draws from observational cohorts, registry data, and expert consensus rather than randomized controlled trials. This is both a limitation and an opportunity: there are legitimate, high-impact investigative questions that a well-mentored fellow can contribute to meaningfully.

Typical scholarly activities during fellowship include:

• Retrospective cohort studies using institutional or registry data — feasible within a one-year timeline with established mentorship
• Prospective biomarker or imaging surveillance protocols embedded in active oncology trials
• Systematic reviews and meta-analyses, particularly in areas where the primary literature is sparse and evidence synthesis is needed
• Case series publications in areas of emerging clinical practice (immunotherapy myocarditis, novel targeted agents)

Two-year research track fellows at programs with active NIH funding or pharmaceutical partnerships may contribute to prospective trial design and conduct, and in some cases develop K-award applications during the fellowship itself.

When evaluating a program's research environment, ask specifically: How many fellows from the past three years have first-author publications from their fellowship work? Who is the primary research mentor, and what is their current funded portfolio? Is protected research time written into the fellowship contract, or is it contingent on clinical volume?

Board Certification Pathway

There is currently no standalone ABIM board examination for cardio-oncology. Fellows who complete cardio-oncology training remain board-certified in cardiovascular disease — the credential they entered fellowship with. Cardio-oncology does not confer an additional ABIM certificate at this time.

Two relevant developments in the certification landscape are worth tracking:

• ICOS Certification: The International Cardio-Oncology Society offers a certification process for cardio-oncology practitioners. This is a society-administered credential, not an ABIM certificate. It signals subspecialty expertise and is recognized within the field, but its weight with hiring committees varies by institution. Verify current requirements and exam structure directly with ICOS for your application year.
• ACC Cardio-Oncology Section: The American College of Cardiology has an active cardio-oncology section that supports curriculum development and credentialing discussions. The landscape of certificates of added qualification and competency frameworks is evolving. Monitor ACC and ABIM communications directly for developments during your training period.

If formal board certification is central to your career planning — for credentialing, hospital privileges, or academic promotion decisions at your target institution — confirm the current status of any certification pathway before committing to a program. The field is moving, and what is accurate at time of writing may be updated within a single application cycle.

How to Find and Evaluate Programs

Because there is no ACGME program directory for cardio-oncology, identifying programs requires active outreach. Starting points include the ICOS program directory, the ACC Cardio-Oncology Section's training resources, and peer networks through your cardiology training program. Published lists in the medical literature periodically survey active programs, though they date quickly.

Once you have identified programs, evaluate them on the following dimensions:

• Case volume and acuity: Ask for the annual cardio-oncology consult volume, clinic volume, and specifically the volume of immunotherapy-related cardiac events and new cardiotoxicity cases. A program at an NCI-designated comprehensive cancer center with a large active oncology census will expose you to qualitatively different cases than a program at an institution without that infrastructure.
• Faculty expertise: Identify the cardiologists and oncologists who will directly supervise you. Review their publication records, society leadership roles, and clinical reputations. A single prominent name associated with a program does not guarantee that person will be your day-to-day mentor.
• Imaging capabilities: Cardiac MRI is increasingly central to cardio-oncology practice, particularly for myocarditis evaluation and cardiac amyloidosis characterization. Confirm whether fellows receive supervised training in cardiac MRI acquisition and interpretation, or only in echocardiography.
• Institutional cancer center designation: NCI-designated cancer centers carry specific infrastructure requirements that support complex oncology volume and research activity. This is not a requirement for a quality program, but it is a useful proxy for the density and complexity of the clinical environment.
• Alumni outcomes: Where have the last three to five fellows gone? Academic faculty positions, NCI cancer center appointments, and hybrid academic-clinical roles suggest the program is training people competitively for the job market it claims to serve. If a program cannot name recent alumni outcomes, that is informative.
• Governance and trainee protections: Since ACGME oversight is absent, ask directly: What are the duty hour expectations? What is the grievance process? Is there a fellow evaluation committee? Is the funding source for your salary stable for the full fellowship year?

Application Process and Timeline

Cardio-oncology fellowships operate entirely outside the NRMP match. There is no centralized application system, no rank order list, and no match day. Programs recruit independently, and the timeline is set by each institution.

In practice, most programs begin recruiting approximately twelve to eighteen months before the fellowship start date — meaning that if you are finishing cardiology fellowship in June, you should be actively contacting programs no later than the prior summer or early fall, and in some cases earlier. Programs with competitive positions at high-volume centers may recruit on an even longer horizon.

A typical application includes:

• CV with publications, presentations, and research history
• Personal statement focused on clinical and academic interests within cardio-oncology specifically
• Letters of recommendation from cardiology fellowship faculty — ideally at least one from a cardiologist with cardio-oncology or cardiac imaging expertise who can speak to your clinical readiness
• In some cases, a research proposal or description of a project you wish to pursue

Because there is no match, offers can be extended and accepted on a rolling basis. This means the strategic calculus differs from NRMP specialties: waiting for a preferred program while holding an offer from a second-choice program is a real decision you may face. Establish your priorities before applications are out, not after offers arrive.

Direct contact with program coordinators and fellowship directors — by email, and where possible through an introduction from a faculty mentor who knows the program — is standard and expected. Cold outreach is normal; a concise, specific email expressing interest and asking about the current application cycle is appropriate.

Compensation, Funding, and Benefits

For compensation figures, benefits structures, and funding comparisons by program type, see the PGY Zero compensation data pages. What is worth stating in general terms:

• Compensation for cardio-oncology fellows typically mirrors institutional PGY-level salary scales at the level you would occupy after completing cardiology fellowship — commonly in the PGY-7 or PGY-8 range. The actual figure varies by institution and by region.
• Some programs, particularly research-track positions, are funded through department grants, foundation awards, or pharmaceutical partnerships rather than through the institution's standard GME budget. This is worth understanding before you accept: grant-funded positions carry a different risk profile if funding is interrupted, and the terms of the research expectations that accompany that funding should be explicit in your offer.
• Without ACGME oversight, benefits — health insurance, malpractice coverage, vacation, parental leave — are set at institutional discretion. Review the benefits package as carefully as the training content. Variation is wide.

Career Outcomes and Job Market

The job market for cardio-oncologists is growing. The underlying drivers — improving cancer survival rates, expanding use of cardiotoxic therapies including immunotherapy, and increased institutional recognition of cardio-oncology as a distinct clinical service — are structural rather than cyclical, which supports a durable demand trend rather than a transient one.

Typical practice settings for cardio-oncology fellowship graduates include:

• Academic medical centers with dedicated cardio-oncology programs, where fellows typically split time between clinical care, teaching, and research
• NCI-designated cancer centers, either freestanding or embedded within academic systems, where clinical volume and research infrastructure are concentrated
• Hybrid clinical-academic roles at community academic programs building cardio-oncology services de novo — a growing category as regional cancer centers seek to develop this expertise locally

Pure private practice cardio-oncology is uncommon; the subspecialty's clinical complexity and research emphasis tend to favor academic or academic-adjacent environments. If you are targeting private practice after fellowship, evaluate whether a cardio-oncology year serves that goal better than additional imaging or heart failure training, and have that conversation explicitly with mentors who know both paths.

Early-career cardio-oncologists entering the academic market should expect to negotiate protected research time, imaging lab affiliations, and oncology program relationships as part of their offer. Programs that have successfully placed graduates into faculty positions can model what that negotiation looks like — another reason alumni outcome data matters during program evaluation.

Professional Societies and Networking

The professional society landscape for cardio-oncology has developed rapidly and offers meaningful infrastructure for fellows:

• International Cardio-Oncology Society (ICOS): the primary society focused exclusively on this subspecialty; runs an annual meeting, fellowship recognition program, mentorship matching, and the certification process described above; active fellow membership is the most direct way to build a national network during training
• ACC Cardio-Oncology Section: within the American College of Cardiology, this section develops guidelines, position statements, and training curricula; fellow membership in ACC with engagement in this section provides access to the broader cardiology leadership network and to ongoing credentialing discussions
• American Society of Echocardiography (ASE): relevant for fellows developing advanced imaging skills; has working groups and educational resources specific to cardio-oncology imaging protocols
• Heart Failure Society of America (HFSA): relevant for the subset of cardio-oncology practice focused on chemotherapy-related cardiomyopathy and survivorship heart failure management

Conference attendance during fellowship — ICOS annual meeting in particular — serves a dual function: scientific education and direct visibility with program directors and faculty from other institutions who influence hiring decisions. Fellows who present work at national meetings early in training build reputations that matter when the academic job market opens.

Frequently Asked Questions

Can I pursue cardio-oncology fellowship after hematology/oncology training rather than cardiology?

Yes, some programs explicitly accept hematology/oncology fellowship graduates. These programs typically provide additional structured cardiology and cardiac imaging training to reach the clinical competency level expected of the fellowship. The number of programs offering this track is smaller than those requiring cardiology as the prerequisite. Identify programs with dual entry pathways early and ask specifically how the curriculum is adapted for your background.

Is there a match for cardio-oncology fellowship?

No. There is no NRMP match or equivalent centralized matching process for cardio-oncology. Programs recruit independently, offers are made directly, and the timeline varies by institution. Direct outreach to programs and to faculty mentors who can make introductions is the standard approach. See the application process section above.

Will doing a cardio-oncology fellowship limit my general cardiology career options?

This is worth thinking through carefully. A cardio-oncology year adds a subspecialty identity on top of your cardiovascular disease training; it does not replace or diminish it. Most cardio-oncology faculty continue to practice general cardiology alongside their subspecialty work, particularly in earlier career stages. What a cardio-oncology year does constrain is time: a year spent in fellowship is a year not spent in practice, accumulating clinical volume, or building a private practice referral base. If your career goal is high-volume interventional or electrophysiology practice, an additional fellowship year in cardio-oncology adds minimal career capital toward that goal. If your goal is academic cardiology with a subspecialty focus at an institution with oncology infrastructure, it is directly valuable.

How competitive are cardio-oncology fellowship positions?

Competitive by any reasonable definition. The number of positions nationally is small relative to the number of graduating cardiovascular disease fellows who have expressed interest in the field. Programs at NCI-designated cancer centers and those with established research records attract applicants from across the country. Research productivity during cardiology fellowship, strong faculty relationships that generate meaningful letters of recommendation, and a clearly articulated clinical and scholarly focus for the fellowship year are the primary differentiators. Cardio-oncology exposure during cardiology fellowship — whether through elective rotations, research projects, or quality improvement work — strengthens an application concretely.

Are ACGME-accredited cardio-oncology programs coming?

The field has been actively discussing formal ACGME accreditation, and professional society working groups have engaged in this process. Whether and when accreditation will be granted, and what requirements would accompany it, is not settled as of this registry's publication. Verify current status directly with the ACGME, ICOS, and ACC for the most recent developments. This is one of the faster-moving structural questions in the field and should be re-evaluated each application cycle.